10/616,365

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	1	("6967212").PN.	USPAT	OR	OFF	2006/12/05 07:56
L2	1	("6414002").PN.	USPAT	OR	OFF	2006/12/05 07:58
L3	1	("6919358").PN.	USPAT	OR	OFF	2006/12/05 07:59
L4	1	("6653314").PN.	USPAT	OR	OFF	2006/12/05 08:00
L5	1	("6727271").PN.	USPAT	OR	OFF	2006/12/05 08:00
L6	1	("7105556").PN.	USPAT	OR	OFF	2006/12/05 08:09
L7	1	("7084162").PN.	USPAT	OR	OFF	2006/12/05 08:09
L8	1	("7053106").PN.	USPAT	OR	OFF	2006/12/05 08:11
L9	1	("6875782").PN.	USPAT	OR	OFF	2006/12/05 08:23
L10	4088	548/235 OR 544/297 OR 514/275 OR 514/374	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/05 08:25
L11	1139	L10 AND (1,3-OXAZOL OR OXAZOLE OR 1,3-OXAZOLYL)	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/05 08:25
L12	545	L11 AND (DIABETES OR DIABETIC OR ANTIDIABETIC OR HYPOGLYCEMIC OR HYPERGLYCEMIA OR INSULIN OR (GLUCOSE ADJ INTOLERANCE))	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/05 08:31
L13	0	L12 AND 2-PHENYL-1,3-OXAZOL	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/05 08:29
L14	3	L12 AND 2-PHENYL-1,3-OXAZOLE	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/05 08:30
L16	93	L12 AND PYRROLIDIN	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT	OR	ON	2006/12/05 08:31

STN SEARCH TRANSCRIPT 10/616,365

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1623zct

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 5	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 6	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS 7	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 8	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS 12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS 13	OCT 19	E-mail format enhanced
NEWS 14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS 15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS 16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS 17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS 18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS 19	NOV 10	CA/CAplus F-Term thesaurus enhanced
NEWS 20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS 21	NOV 13	CA/CAplus pre-1967 chemical substance index entries enhanced with preparation role
NEWS 22	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS 23	NOV 20	CA/CAplus to MARPAT accession number crossover limit increased to 50,000
NEWS 24	NOV 20	CA/CAplus patent kind codes will be updated
NEWS 25	DEC 01	CAS REGISTRY updated with new ambiguity codes

NEWS EXPRESS NOVEMBER 10 CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:49:24 ON 05 DEC 2006

=> FILE REG

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	1.68	1.68

FILE 'REGISTRY' ENTERED AT 08:54:04 ON 05 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 DEC 2006 HIGHEST RN 914768-89-1
DICTIONARY FILE UPDATES: 4 DEC 2006 HIGHEST RN 914768-89-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\CHENG et al ANTIDIABETIC ANTIOBESITY.str



- ALL RINGS ISOLATED -

chain nodes :
23
ring nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
chain bonds :
13-23 22-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-8 7-11 8-9 9-10 10-11 12-13 12-16 13-14 14-15 15-16 17-18 17-22 18-19 19-20 20-21 21-22
exact/norm bonds :
8-9 9-10 12-16 15-16
exact bonds :
7-8 7-11 10-11 12-13 13-14 13-23 14-15 22-23
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 17-18 17-22 18-19 19-20 20-21 21-22
isolated ring systems :
containing 1 : 7 : 12 : 17 :

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 21:Atom 22:Atom 23:CLASS

L1 STRUCTURE UPLOADED

=> D L1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> S L1
SAMPLE SEARCH INITIATED 08:55:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 53 TO ITERATE

100.0% PROCESSED 53 ITERATIONS 13 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 624 TO 1496
PROJECTED ANSWERS: 44 TO 476

L2 13 SEA SSS SAM L1

=> S L1 SSS FULL
FULL SEARCH INITIATED 08:55:36 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1556 TO ITERATE

100.0% PROCESSED 1556 ITERATIONS 412 ANSWERS
SEARCH TIME: 00.00.01

L3 412 SEA SSS FUL L1

=> FILE CAPLUS
COST IN U.S. DOLLARS SINCE FILE ENTRY 167.82 TOTAL SESSION 169.50

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 08:55:40 ON 05 DEC 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 5 Dec 2006 VOL 145 ISS 24
FILE LAST UPDATED: 4 Dec 2006 (20061204/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> S L3
L4 9 L3

=> D 1-9

L4 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:1031178 CAPLUS
DN 145:419138
TI Preparation of 3-benzylpyrrolidin-2-one and N-benzylimidazolidin-2-one derivatives as prophylactic/therapeutic agents for diabetes
IN Cho, Nobuo; Kasai, Shizuo; Yamashita, Toshiro
PA Takeda Pharmaceutical Company Limited, Japan
SO PCT Int. Appl., 743pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006104280	A1	20061005	WO 2006-JP307402	20060331

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRAI JP 2005-102913	A	20050331		
JP 2005-306397	A	20051020		

RE.CNT 71 THERE ARE 71 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:979406 CAPLUS
TI Determination of the absolute configuration and solution conformation of a novel disubstituted pyrrolidine acid A by vibrational circular dichroism
AU Freedman, Teresa B.; Cao, Xiaolin; Phillips, Linda M.; Cheng, Peter T. W.; Dalterio, Richard; Shu, Yue-Zhong; Zhang, Hao; Zhao, Ning; Shukla, Rajesh B.; Tymiak, Adrienne; Gozo, Stephen K.; Nafie, Laurence A.; Gougoutas, Jack Z.
CS Department of Chemistry, Syracuse University, Syracuse, NY, USA
SO Chirality (2006), 18(9), 746-753
CODEN: CHRLEP; ISSN: 0899-0042

PB Wiley-Liss, Inc.
DT Journal
LA English
RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2006:365266 CAPLUS
DN 144:412357
TI Preparation of azetidinyl-, pyrrolidinyl-, and piperidinylphenylbenzenesulfonamides and related compounds as dopamine D3 receptor ligands.
IN Drescher, Karla; Haupt, Andreas; Unger, Liliane; Turner, Sean C.; Braje, Wilfried; Grandel, Roland; Henry, Christophe; Backfisch, Gisela; Beyerbach, Armin; Lubisch, Wilfried
PA Abbott Gmbh & Co. KG, Germany
SO PCT Int. Appl., 191 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2006040182	A1	20060420	WO 2005-EP11106	20051014
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRAI US 2004-618878P	P	20041014		

OS MARPAT 144:412357
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:465484 CAPLUS
DN 141:190671
TI Syntheses and SAR studies of 4-(heteroarylpiperidin-1-yl-methyl)-pyrrolidin-1-yl-acetic acid antagonists of the human CCR5 chemokine receptor
AU Shankaran, K.; Donnelly, Karla L.; Shah, Shrenik K.; Guthikonda, Ravindra N.; MacCoss, Malcolm; Mills, Sander G.; Gould, Sandra L.; Malkowitz, Lorraine; Siciliano, Salvatore J.; Springer, Martin S.; Carella, Anthony; Carver, Gwen; Hazuda, Daria; Holmes, Karen; Kessler, Joseph; Lineberger, Janet; Miller, Michael D.; Emini, Emilio A.; Schleif, William A.
CS Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ, 07065, USA
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(13), 3419-3424
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 141:190671
RE.CNT 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2004:41231 CAPLUS
DN 140:111429
TI Preparation of substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents
IN Cheng, Peter T. W.; Chen, Sean; Devasthale, Pratik; Ding, Charles Z.; Herpin, Timothy F.; Wu, Shung; Zhang, Hao; Wang, Wei; Ye, Xiang-Yang
PA Bristol-Myers Squibb Company, USA
SO PCT Int. Appl., 543 pp.
CODEN: PIXXD2
DT Patent
LA English

APPLICANTS

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2004004665	A2	20040115	WO 2003-US22149	20030702
WO 2004004665	A3	20040325		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003259131	A1	20040123	AU 2003-259131	20030702
JP 2005536494	T2	20051202	JP 2004-520148	20030702
EP 1656368	A2	20060517	EP 2003-763485	20030702
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004063700	A1	20040401	US 2003-616365	20030708
NO 2005000077	A	20050203	NO 2005-77	20050106
PRAI US 2002-394508P	P	20020709		
WO 2003-US22149	W	20030702		

OS MARPAT 140:111429

L4 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2003:796420 CAPLUS
DN 139:308007
TI Preparation of peptides as immunosuppressants
IN Nagy, Zoltan; Brandstetter, Tilmann
PA GPC Biotech AG, Germany
SO PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003082197	A2	20031009	WO 2003-US9219	20030324
WO 2003082197	A3	20040715		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2479939	AA	20031009	CA 2003-2479939	20030324
AU 2003218401	A1	20031013	AU 2003-218401	20030324
EP 1494701	A2	20050112	EP 2003-714400	20030324
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

	BR 2003008654	A	20050222	BR 2003-8654	20030324
	CN 1652810	A	20050810	CN 2003-811094	20030324
	JP 2005533753	T2	20051110	JP 2003-579740	20030324
	US 2006004077	A1	20060105	US 2005-508504	20050606
PRAI	US 2002-367123P	P	20020322		
	WO 2003-US9219	W	20030324		

OS MARPAT 139:308007

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:675993 CAPLUS
DN 137:216874
TI Acylated piperidine derivatives, specifically 1-(pyrrolidinylcarbonyl)piperidines, 1-(piperidinylcarbonyl)piperidines, and analogs, as melanocortin-4 receptor agonists, and their pharmaceutical compositions and therapeutic uses
IN Ujjainwalla, Feroze; Chu, Lin; Goulet, Mark T.; Lee, Bonnie; Warner, Daniel; Wyvratt, Matthew J.
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002068388	A2	20020906	WO 2002-US5724	20020225
	WO 2002068388	A3	20030313		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2439152	AA	20020906	CA 2002-2439152	20020225
	EE 200300415	A	20031215	EE 2003-415	20020225
	EP 1383501	A2	20040128	EP 2002-728357	20020225
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	HU 200303376	A2	20040128	HU 2003-3376	20020225
	JP 2004529105	T2	20040924	JP 2002-567902	20020225
	NZ 527364	A	20041224	NZ 2002-527364	20020225
	CN 1633297	A	20050629	CN 2002-805674	20020225
	BR 2002007658	A	20051025	BR 2002-7658	20020225
	US 2003225060	A1	20031204	US 2003-356879	20030203
	US 6818658	B2	20041116		
	ZA 2003006160	A	20040721	ZA 2003-6160	20030808
	BG 108132	A	20041230	BG 2003-108132	20030825
	NO 2003003812	A	20031028	NO 2003-3812	20030827
	US 2004266821	A1	20041230	US 2004-894719	20040720
PRAI	US 2001-272258P	P	20010228		
	US 2001-300118P	P	20010622		
	WO 2002-US5724	W	20020225		
	US 2003-356897	A3	20030203		

OS MARPAT 137:216874

L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2000:725463 CAPLUS
DN 133:296374
TI Preparation of pyrrolidine modulators of chemokine receptor activity
IN Chapman, Kevin; Hale, Jeffrey; Kim, Dooseop; Lynch, Christopher; Shah, Shrenik; Shankaran, Kothandaraman; Shen, Dong-ming; Willoughby, Christopher; Maccoss, Malcolm; Mills, Sander G.; Loebach, Jennifer L.; Guthikonda, Ravindra N.
PA Merck & Co., Inc., USA; et al.
SO PCT Int. Appl., 455 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000059502	A1	20001012	WO 2000-US8996	20000405
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6248755	B1	20010619	US 2000-542617	20000404
	CA 2373717	AA	20001012	CA 2000-2373717	20000405
	EP 1171122	A1	20020116	EP 2000-921700	20000405
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
	JP 2002541103	T2	20021203	JP 2000-609066	20000405
	AU 767179	B2	20031106	AU 2000-41979	20000405
PRAI	US 1999-128033P	P	19990406		
	WO 2000-US8996	W	20000405		

OS MARPAT 133:296374
RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
AN 1997:220630 CAPLUS
DN 126:212136
TI Preparation of 4,5-diaryloxazole derivatives as prostaglandin I2 antagonists.
IN Taniguchi, Kiyoshi; Hattori, Kouji; Tsubaki, Kazunori; Okitsu, Osamu; Tabuchi, Seiichiro
PA Fujisawa Pharmaceutical Co., Ltd., Japan
SO PCT Int. Appl., 138 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9703973	A1	19970206	WO 1996-JP1996	19960718
	W: AU, CA, CN, HU, JP, KR, MX, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	TW 401408	B	20000811	TW 1996-85108673	19960717
	CA 2227442	AA	19970206	CA 1996-2227442	19960718
	ZA 9606126	A	19970210	ZA 1996-6126	19960718
	AU 9664697	A1	19970218	AU 1996-64697	19960718
	AU 716304	B2	20000224		
	EP 842161	A1	19980520	EP 1996-924137	19960718
	EP 842161	B1	20020918		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	CN 1196726	A	19981021	CN 1996-197084	19960718
	CN 1095839	B	20021211		
	JP 11509191	T2	19990817	JP 1997-504319	19960718
	HU 9900881	A2	19990830	HU 1999-881	19960718
	EP 1213285	A2	20020612	EP 2002-3081	19960718
	EP 1213285	A3	20020703		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI

	AT 224380	E	20021015	AT 1996-924137	19960718
	PT 842161	T	20030228	PT 1996-924137	19960718
	ES 2181902	T3	20030301	ES 1996-924137	19960718
	US 5972965	A	19991026	US 1998-983139	19980121
	US 6300344	B1	20011009	US 1999-357664	19990720
PRAI	GB 1995-15085	A	19950721		
	AU 1996-9002	A	19960329		
	EP 1996-924137	A3	19960718		
	WO 1996-JP1996	W	19960718		
	US 1998-983139	A3	19980121		

OS MARPAT 126:212136

7-9 ARE PRIOR ART ONLY

NONE OF THE NON-PRIOR-ART HITS IN #L4 ARE ANTIDIABETIC COMPOUNDS.

=> D 7-9 IBIB ABS HITSTR

L4 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:675993 CAPLUS
DOCUMENT NUMBER: 137:216874
TITLE: Acylated piperidine derivatives, specifically 1-(pyrrolidinylcarbonyl)piperidines, 1-(piperidinylcarbonyl)piperidines, and analogs, as melanocortin-4 receptor agonists, and their pharmaceutical compositions and therapeutic uses
INVENTOR(S): Ujjainwalla, Feroze; Chu, Lin; Goulet, Mark T.; Lee, Bonnie; Warner, Daniel; Wyvratt, Matthew J.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002068388	A2	20020906	WO 2002-US5724	20020225
WO 2002068388	A3	20030313		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2439152	AA	20020906	CA 2002-2439152	20020225
EE 200300415	A	20031215	EE 2003-415	20020225
EP 1383501	A2	20040128	EP 2002-728357	20020225
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 200303376	A2	20040128	HU 2003-3376	20020225
JP 2004529105	T2	20040924	JP 2002-567902	20020225
NZ 527364	A	20041224	NZ 2002-527364	20020225
CN 1633297	A	20050629	CN 2002-805674	20020225
BR 2002007658	A	20051025	BR 2002-7658	20020225
US 2003225060	A1	20031204	US 2003-356879	20030203
US 6818658	B2	20041116		
ZA 2003006160	A	20040721	ZA 2003-6160	20030808
BG 108132	A	20041230	BG 2003-108132	20030825
NO 2003003812	A	20031028	NO 2003-3812	20030827
US 2004266821	A1	20041230	US 2004-894719	20040720
PRIORITY APPLN. INFO.:			US 2001-272258P P	20010228
			US 2001-300118P P	20010622
			WO 2002-US5724 W	20020225
			US 2003-356897 A3	20030203

OTHER SOURCE(S): MARPAT 137:216874
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Certain novel 4-substituted N-acylated piperidine derivs., specifically I, are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R) [wherein: p = 1 or 2; q = 0, 1, or 2; n = 0, 1, or 2; R1 = H, amidino, alkyliminoyl, (un)substituted alkyl, (CH2)n-G1 [G1 = (un)substituted cycloalkyl, Ph, naphthyl, or heteroaryl]; R2 = (un)substituted Ph, naphthyl, or heteroaryl; X = alkyl, (CH2)n-G2 [G2 = (un)substituted cycloalkyl, Ph, naphthyl, heteroaryl, heterocyclyl, cyano, CONH2, CO2H, OH, NH2, and various derivs.] where any of (CH2)n may also be substituted; including pharmaceutically acceptable salts]. They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Approx. 180 invention compds. I and approx. 25 intermediates were prepared For instance, (2-bromo-5-chlorophenyl)acetic acid underwent a sequence of Me esterification, coupling with tert-Bu 4-[[(trifluoromethyl)sulfonyl]oxy]-3,6-dihydropyridine-1(2H)-carboxylate via a boronate ester, removal of the BOC group, and amidation with (3S,4R)-1-(tert-butyl)-4-(2,4-difluorophenyl)pyrrolidine-3-carboxylic acid. The unsatd. amide-ester underwent hydrogenation, saponification of the ester, and amidation with MeNH2.HCl, to give title compound II. Representative compds. I bound to cloned human MC-4R in vitro with IC50 values generally below 2 μM, and also acted as agonists toward cloned human MCR in a functional assay with EC50 values less than 1 μM.

IT 455957-21-8P 455957-22-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of acylated piperidine derivs., particularly (pyrrolidinylcarbonyl)piperidines, (piperidinylcarbonyl)piperidines, and analogs, as melanocortin-4 receptor agonists)

RN 455957-21-8 CAPLUS
CN 4-Oxazolecarboxamide, N-[2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 455957-22-9 CAPLUS
CN 5-Oxazolecarboxamide, N-[2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:725463 CAPLUS
DOCUMENT NUMBER: 133:296374
TITLE: Preparation of pyrrolidine modulators of chemokine receptor activity
INVENTOR(S): Chapman, Kevin; Hale, Jeffrey; Kim, Dooseop; Lynch, Christopher; Shah, Shrenik; Shankaran, Kothandaraman; Shen, Dong-ming; Willoughby, Christopher; Maccoss, Malcolm; Mills, Sander G.; Loebach, Jennifer L.; Guthikonda, Ravindra N.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; et al.
SOURCE: PCT Int. Appl., 455 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000059502	A1	20001012	WO 2000-US8996	20000405
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6248755	B1	20010619	US 2000-542617	20000404
CA 2373717	AA	20001012	CA 2000-2373717	20000405
EP 1171122	A1	20020116	EP 2000-921700	20000405
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002541103	T2	20021203	JP 2000-609066	20000405
AU 767179	B2	20031106	AU 2000-41979	20000405
PRIORITY APPLN. INFO.:			US 1999-128033P P	19990406
			WO 2000-US8996 W	20000405

OTHER SOURCE(S): MARPAT 133:296374
GI



I II

AB The title compds. [I; R1 = CO2H, NO2, tetrazolyl, etc.; R2 = (un)substituted piperidino, 1,2,3,6-tetrahydropyridin-1-yl; piperazino; R3 = (un)substituted Ph, naphthyl, heterocyclyl; R4 = (un)substituted alkyl, cycloalkyl, alkylcycloalkyl, etc.; R5 = H, (un)substituted alkyl; R4 and R5 may be joined together to form (un)substituted cycloalkyl; R6 = H, (un)substituted alkyl; R14 = H, alkyl; n = 0-3] and their pharmaceutically acceptable salts, modulators of chemokine receptor activity, in particular, modulators of the chemokine receptors CCR-5 and/or CCR-3, and therefore useful in treating AIDS, were prepared E.g., a multi-step synthesis of II.CF3CO2H was given. The compds. I had activity in binding to CCR-5 or the CCR-3 receptor, generally with an IC50 of < 1 μM.

IT 301212-27-1P 301212-34-0P 301216-59-1P
301216-60-4P 301216-61-5P 301216-62-6P
301216-63-7P 301216-64-8P 301216-65-9P
301216-66-0P 301216-67-1P 301216-68-2P
301216-69-3P 301216-70-6P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolidine modulators of chemokine receptor activity)

RN 301212-27-1 CAPLUS
CN 1-Pyrrolidineacetic acid, α-cyclohexyl-3-phenyl-4-[[4-[4-(phenylmethyl)-2-oxazolyl]-1-piperidinyl]methyl]-, (αR,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 301212-34-0 CAPLUS
CN 1-Pyrrolidineacetic acid, α-(cyclobutylmethyl)-3-(3-fluorophenyl)-4-[[4-[4-(phenylmethyl)-2-oxazolyl]-1-piperidinyl]methyl]-, (αR,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 301216-59-1 CAPLUS
CN 1-Pyrrolidineacetic acid, 3-(3-fluorophenyl)-α-(1-methylethyl)-4-[[4-[2-(phenylmethyl)-5-oxazolyl]-1-piperidinyl]methyl]-, (αR,3S,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 301216-60-4 CAPLUS
CN 1-Pyrrolidineacetic acid, α-(cyclobutylmethyl)-3-(3-fluorophenyl)-4-[[4-[2-(phenylmethyl)-5-oxazolyl]-1-piperidinyl]methyl]-, (αR,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 301216-61-5 CAPLUS
CN 1-Pyrrolidineacetic acid, α-(cyclopropylmethyl)-3-(3-fluorophenyl)-4-[[4-[2-(phenylmethyl)-5-oxazolyl]-1-piperidinyl]methyl]-, (αR,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 301216-62-6 CAPLUS
CN 1-Pyrrolidineacetic acid, α-(cyclobutylmethyl)-3-[[4-[4-ethyl-2-(phenylmethyl)-5-oxazolyl]-1-piperidinyl]methyl]-4-(3-fluorophenyl)-, (αR,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 301216-63-7 CAPLUS
CN 1-Pyrrolidineacetic acid, 3-[[4-[4-ethyl-2-(phenylmethyl)-5-oxazolyl]-1-piperidinyl]methyl]-4-(3-fluorophenyl)-α-(1-methylethyl)-, (αR,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 301216-64-8 CAPLUS
CN 1-Pyrrolidineacetic acid, α-(cyclopropylmethyl)-3-[[4-[4-ethyl-2-(phenylmethyl)-5-oxazolyl]-1-piperidinyl]methyl]-4-(3-fluorophenyl)-, (αR,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 301216-65-9 CAPLUS
CN 1-Pyrrolidineacetic acid, 3-(3-fluorophenyl)-4-[[4-[2-[(4-fluorophenyl)methyl]-5-oxazolyl]-1-piperidinyl]methyl]-α-(1-methylethyl)-, (αR,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 301216-66-0 CAPLUS
CN 1-Pyrrolidineacetic acid, α-(cyclopropylmethyl)-3-(3-fluorophenyl)-4-[[4-[2-[(4-fluorophenyl)methyl]-5-oxazolyl]-1-piperidinyl]methyl]-, (αR,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 301216-67-1 CAPLUS
CN 1-Pyrrolidineacetic acid, α-(1,1-dimethylethyl)-3-[[4-[4-ethyl-2-(phenylmethyl)-5-oxazolyl]-1-piperidinyl]methyl]-4-(3-fluorophenyl)-, (αR,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 301216-68-2 CAPLUS
CN 1-Pyrrolidineacetic acid, 3-[[4-[2-[(4-chlorophenyl)methyl]-5-oxazolyl]-1-piperidinyl]methyl]-4-(3-fluorophenyl)-α-(1-methylethyl)-, (αR,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 301216-69-3 CAPLUS
CN 1-Pyrrolidineacetic acid, 3-(3-fluorophenyl)-α-(1-methylethyl)-4-[[4-[2-[[4-(trifluoromethyl)phenyl]methyl]-5-oxazolyl]-1-piperidinyl]methyl]-, (αR,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 301216-70-6 CAPLUS
CN 1-Pyrrolidineacetic acid, 3-[[4-[2-[(4-chlorophenyl)methyl]-4-ethyl-5-oxazolyl]-1-piperidinyl]methyl]-4-(3-fluorophenyl)-α-(1-methylethyl)-, (αR,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 301221-78-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrrolidine modulators of chemokine receptor activity)
RN 301221-78-3 CAPLUS
CN 1-Pyrrolidineacetic acid, 3-(3-fluorophenyl)-α-(1-methylethyl)-4-[[4-[2-(phenylmethyl)-5-oxazolyl]-1-piperidinyl]methyl]-, (3-methoxyphenyl)methyl ester, (αR,3S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1997:220630 CAPLUS
DOCUMENT NUMBER: 126:212136
TITLE: Preparation of 4,5-diaryloxazole derivatives as prostaglandin I2 antagonists.
INVENTOR(S): Taniguchi, Kiyoshi; Hattori, Kouji; Tsubaki, Kazunori; Okitsu, Osamu; Tabuchi, Seiichiro
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 138 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9703973	A1	19970206	WO 1996-JP1996	19960718
W: AU, CA, CN, HU, JP, KR, MX, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
TW 401408	B	20000811	TW 1996-85108673	19960717
CA 2227442	AA	19970206	CA 1996-2227442	19960718
ZA 9606126	A	19970210	ZA 1996-6126	19960718
AU 9664697	A1	19970218	AU 1996-64697	19960718
AU 716304	B2	20000224		
EP 842161	A1	19980520	EP 1996-924137	19960718
EP 842161	B1	20020918		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
CN 1196726	A	19981021	CN 1996-197084	19960718
CN 1095839	B	20021211		
JP 11509191	T2	19990817	JP 1997-504319	19960718
HU 9900881	A2	19990830	HU 1999-881	19960718
EP 1213285	A2	20020612	EP 2002-3081	19960718
EP 1213285	A3	20020703		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
AT 224380	E	20021015	AT 1996-924137	19960718
PT 842161	T	20030228	PT 1996-924137	19960718
ES 2181902	T3	20030301	ES 1996-924137	19960718
US 5972965	A	19991026	US 1998-983139	19980121
US 6300344	B1	20011009	US 1999-357664	19990720

PRIORITY APPLN. INFO.:

GB 1995-15085	A	19950721
AU 1996-9002	A	19960329
EP 1996-924137	A3	19960718
WO 1996-JP1996	W	19960718
US 1998-983139	A3	19980121

OTHER SOURCE(S): MARPAT 126:212136
GI



I

AB Title compds. [I; R1 = (protected) carboxy; , R2, R3 = (substituted) aryl; R4 = H, alkyl, OH, aryl; A1 = lower alkylene; A2 = R4-substituted Ph, dihydronaphthyl, tetrahydronaphthyl, indanyl; A3 = A4A5; A4 = bond, CH2, CO; A5 = (substituted) cycloalkenyl, cycloalkyl, bicycloheptyl, bicycloheptenyl, tetrahydrofuryl, tetrahydrothienyl, azetidinyl, pyrrolidinyl, piperidinyl; n = 0, 1], were prepared Thus, 2-(4,5-diphenyloxazol-2-yl)-3-(3-tert-butyldiphenylsilyloxybenzyl)tetrahydrofuran (preparation given) in THF was treated with Bu4NF and the product was stirred with EtO2CCH2Br and K2CO3 in DMF to give Et [3-[[2-(4,5-diphenyloxazol-2-yl)tetrahydrofuran-3-yl]methyl]phenoxy]acetate. Na [3-[[2-(4,5-diphenyloxazol-2-yl)-2-cyclohepten-1-yl]methyl]phenoxy]acetate at 10-7 M gave 88% inhibition of ADP-induced human platelet aggregation.
IT 187992-00-3P 187992-08-1P 187992-13-8P
187992-14-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 4,5-diaryloxazole derivs. as prostaglandin I2 antagonists)

RN 187992-00-3 CAPLUS
CN Acetic acid, [3-[[2-(4,5-diphenyl-2-oxazolyl)-1-(phenylmethyl)-3-pyrrolidinyl]methyl]phenoxy]-, ethyl ester (9CI) (CA INDEX NAME)



RN 187992-08-1 CAPLUS
CN Acetic acid, [3-[[2-(4,5-diphenyl-2-oxazolyl)-1-(phenylmethyl)-3-pyrrolidinyl]methyl]phenoxy]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 187992-13-8 CAPLUS
CN Acetic acid, [3-[[2-(4,5-diphenyl-2-oxazolyl)-3-pyrrolidinyl]methyl]phenoxy]- (9CI) (CA INDEX NAME)



RN 187992-14-9 CAPLUS
CN Acetic acid, [3-[[1-acetyl-2-(4,5-diphenyl-2-oxazolyl)-3-pyrrolidinyl]methyl]phenoxy]- (9CI) (CA INDEX NAME)



IT 187993-32-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 4,5-diaryloxazole derivs. as prostaglandin I2 antagonists)
RN 187993-32-4 CAPLUS
CN Oxazole, 2-[3-[(3-methoxyphenyl)methyl]-1-(phenylmethyl)-2-pyrrolidinyl]-4,5-diphenyl- (9CI) (CA INDEX NAME)



=> D 2 HITSTR

L4 ANSWER 2 OF 9 CAPLUS COPYRIGHT 2006 ACS on STN
IT 646998-75-6
RL: PRP (Properties)
(ab initio and vibrational CD and IR spectroscopy on determination of absolute
configuration and solution conformation of disubstituted pyrrolidine acid)
RN 646998-75-6 CAPLUS
CN 1,3-Pyrrolidinedicarboxylic acid, 4-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, 1-phenyl ester, (3R,4S)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



=> LOG HOLD

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	32.10	201.60

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-2.25	-2.25

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 09:01:10 ON 05 DEC 2006